Safety and tolerability of concurrent natalizumab treatment for patients with Crohnʼs disease not in remission while receiving infliximab

The combination of natalizumab plus infliximab was well tolerated. Several positive trends suggested that treating patients not in remission with infliximab plus natalizumab had greater efficacy than treatment with infliximab alone.